

FORGEOS FULFILLMENT LLC

Safety Data Sheet (SDS)

BPC-157 / TB-500 (Wolverine) Blend

Document ID: SDS-FORGE-AM-003	Revision: 1.0 - RELEASED	Prepared: 2026-08-30
Status: RELEASED FOR DISTRIBUTION	Format: OSHA 16-section SDS	Language: English (US)

RELEASED FOR DISTRIBUTION

Issued by ForgeOS Fulfillment LLC using the confirmed formulation representation, matched public formulation references, and available lot COAs. Maintain this SDS with the product and revise it when new or contradictory hazard information becomes available.

1. Identification

Product identifier: BPC-157 / TB-500 (Wolverine) Blend

Covered product codes: The following ForgeOS catalog products are covered because their formulation is identical across the listed fill quantities; only the labeled amount and package size vary.

SKU	Product / Strength	SKU	Product / Strength
bb10	BPC157/TB500 (Wolverine) (10 mg total/vial)		

Recommended use: Laboratory research, analytical, and in-vitro research use by trained personnel.

Restrictions on use: Not for human or veterinary use. Not a food, drug, cosmetic, dietary supplement, household product, or medical advice. Do not administer, ingest, inhale, or use for diagnosis or treatment.

Responsible party: ForgeOS Fulfillment LLC, 6448 NW Colgate Street, Port Saint Lucie, Florida 34986, United States | 561-236-7332 | support@forgeosfulfillment.com

Emergency information: For a life-threatening emergency call 911. In the United States, Poison Help: 1-800-222-1222. For ForgeOS product and business information call 561-236-7332. This business number is not represented as a 24-hour emergency line.

2. Hazard(s) identification

Classification: Not classified as hazardous under the OSHA Hazard Communication Standard based on the confirmed formulation representation, matched public reference SDS, and currently available information.

Signal word / pictograms: None required under the adopted OSHA HCS classification. The research material remains incompletely characterized toxicologically and should be handled conservatively.

Hazards not otherwise classified: Mixture of biologically active research peptides with incomplete occupational toxicology; handle as a research material and avoid unintended exposure. Fine powder or dried residue may irritate eyes, skin, or the respiratory tract. Accidental self-exposure may have unknown pharmacological or immunological effects.

Precautionary measures: Avoid breathing dust, aerosol, or mist. Avoid eye, skin, and clothing contact. Use suitable containment and personal protective equipment. Wash thoroughly after handling. Do not eat, drink, smoke, or apply cosmetics in the work area. Prevent release to drains and the environment.

3. Composition / information on ingredients

Chemical identity	CAS / Identifier	Formula	Molecular weight	Composition / formulation basis
BPC-157 acetate	1628202-19-6	C62H98N16O22 .xC2H4O2	1419.54 (free peptide basis)	Approximately 1:1 by peptide mass with thymosin beta-4; lot COA controls
Thymosin beta-4 (TB-500)	77591-33-4	C212H350N56O78S	4963.4	Approximately 1:1 by peptide mass with BPC-157 acetate; lot COA controls

CONFIRMED FORMULATION BASIS

BPC-157 acetate and full-length thymosin beta-4 in an approximately 1:1 peptide-mass ratio. Covered lots include approximately 10 mg and 20 mg total-fill configurations; the lot COA controls.

Release basis and evidence record

ForgeOS issued this SDS using the confirmed formulation representation, matched public SDS information, and available lot COAs.

Release element	Status	Evidence basis
Responsible party	APPROVED	ForgeOS Fulfillment LLC identity and contact information
Emergency information	APPROVED	911 / Poison Help and ForgeOS business/technical contact statement
Chemical identity	MATCHED	BPC-157 acetate and full-length thymosin beta-4 in an approximately 1:1 peptide-mass ratio. Covered lots include approximately 10 mg and 20 mg total-fill configurations; the lot COA controls.
Formulation	CONFIRMED	ForgeOS responsible-party formulation representation dated 2026-08-30: Source Power products are the same chemical forms and formulations as the matched public reference SDSs.
Lot quality evidence	REVIEWED	Lot 062226: BPC-157 5.32 mg; thymosin beta-4 5.15 mg; 99.02% peptide purity. Lot FH-BB20-01: BPC-157 10.65 mg; TB-500 10.23 mg; 20.88 mg total; 99.60% peptide purity.
Hazard determination	RELEASED	Not classified as hazardous under OSHA HCS based on the matched formulation and available information
Storage and transport	RELEASED	Matched reference storage guidance; not regulated as dangerous goods under DOT/IATA/IMDG
Document approval	APPROVED	ForgeOS responsible-party approval recorded 2026-08-30; Revision 1.0

4. First-aid measures

Inhalation: Move the person to fresh air. Keep at rest and monitor for symptoms. Obtain medical advice if exposure was significant or any symptom develops. If breathing is difficult, trained personnel may provide oxygen. Call emergency services for severe symptoms.

Skin contact: Remove contaminated clothing. Wash skin with soap and plenty of water for at least 15 minutes. Obtain medical advice for persistent irritation or suspected systemic exposure. Launder clothing before reuse.

Eye contact: Rinse cautiously with clean water for at least 15 minutes, lifting upper and lower eyelids. Remove contact lenses if easy to do. Continue rinsing and obtain medical advice.

Ingestion: Rinse mouth. Do not induce vomiting unless directed by medical personnel or Poison Control. Never give anything by mouth to an unconscious person. Contact Poison Control or a physician promptly.

Most important symptoms/effects: Substance-specific acute and delayed effects are not adequately characterized. Irritation, allergic response, or pharmacological effects are possible. Treat any unintended exposure as medically significant.

Medical attention: Provide this SDS, product label, lot number, and COA to medical personnel. Treatment should be symptomatic and supportive; no product-specific antidote is known from the reviewed information.

5. Fire-fighting measures

Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical, or carbon dioxide as appropriate for the surrounding fire.

Specific hazards: The packaged quantity is small. Dry organic material may burn or decompose in a fire. Thermal decomposition may produce carbon oxides and nitrogen oxides and sulfur oxides.

Fire-fighter protection: Wear positive-pressure self-contained breathing apparatus and full protective equipment. Cool intact containers with water spray when safe. Avoid contaminated fire-water runoff.

6. Accidental release measures

Personal precautions: Restrict access. Avoid generating dust or aerosol. Ventilate the area. Wear gloves, protective clothing, and eye protection; use appropriate respiratory protection when airborne material may be present.

Containment and cleanup: For dry material, gently cover and collect with damp absorbent or a HEPA-filtered vacuum; do not dry sweep. For liquid, absorb with inert material. Place waste and contaminated disposables in a sealed, labeled container. Clean the surface using a method appropriate for the research material and facility.

Environmental precautions: Prevent entry into drains, surface water, soil, and uncontrolled waste. Report releases when required by applicable law or facility procedure.

7. Handling and storage

Safe handling: Handle only by trained personnel in a laboratory or controlled work area. Use engineering controls that minimize dust and aerosol. Keep containers closed except during controlled transfer. Avoid sharps injury and accidental self-administration. Follow facility hygiene, spill, and exposure-response procedures.

Storage: Keep tightly closed, dry, and protected from light. Store lyophilized material at -20 C unless the product label states otherwise.

Incompatibilities: Avoid strong oxidizing agents, strong acids or bases, excessive heat, moisture, direct light, and conditions that compromise the container. No additional product-specific incompatibility information is available.

8. Exposure controls / personal protection

Exposure limits: No OSHA PEL, ACGIH TLV, or manufacturer occupational exposure limit has been established for the named research material based on the reviewed information. This does not mean unlimited exposure is acceptable.

Engineering controls: Use a closed process, ventilated enclosure, biological safety cabinet, or local exhaust as appropriate to the task and risk assessment. Provide an eyewash and handwashing facilities. Avoid recirculating contaminated air.

Eye/face protection: Safety glasses with side shields as a minimum; use chemical splash goggles or a face shield when splash, aerosol, or pressurized transfer is possible.

Skin protection: Wear a laboratory coat and suitable disposable chemical-resistant gloves. Select glove material and change frequency through a task-specific assessment. Replace contaminated or damaged gloves immediately.

Respiratory protection: Normally use effective containment. If airborne exposure cannot be controlled, use a NIOSH-approved respirator selected, fitted, and used under a compliant respiratory-protection program.

9. Physical and chemical properties

Physical state	Lyophilized powder blend
Color / appearance	White to off-white lyophilized powder or cake
Odor / odor threshold	No applicable information available
Melting/freezing point	No applicable information available
Boiling point / range	No applicable information available
Flammability / explosion limits	No applicable product-specific information available
Flash point / auto-ignition / decomposition	No applicable product-specific information available
pH	No applicable information available for the dry material
Solubility	Not established for the verified product; do not infer compatibility or reconstitution instructions from this SDS
Vapor pressure / density / viscosity	No applicable product-specific information available
Particle characteristics	Lyophilized cake or powder; particle-size distribution not established

10. Stability and reactivity

Reactivity: No applicable product-specific reactivity data are available. Handle as a sensitive research material.

Chemical stability: Expected to remain stable under the stated storage conditions in the intact original container. Product-specific long-term stability data are not available in this SDS.

Hazardous reactions: No hazardous polymerization or other hazardous reaction is known from the reviewed information. Do not interpret this as a complete compatibility assessment.

Conditions to avoid: Heat, moisture, direct light, contamination, incompatible pH, vigorous aerosol-generating handling, and damaged packaging.

Incompatible materials: Strong oxidizers, strong acids, strong bases, and reactive cleaning agents unless compatibility has been demonstrated.

Hazardous decomposition products: Carbon oxides and nitrogen oxides, sulfur oxides; other irritating or toxic fumes may form during combustion or decomposition.

11. Toxicological information

Likely exposure routes: Inhalation of dust or aerosol, eye contact, skin contact, ingestion, and accidental injection or sharps exposure.

Acute toxicity: No reliable product-specific numerical acute-toxicity values are available for the shipped formulation. The matched public SDS does not classify the product for acute toxicity; handle conservatively because occupational toxicology is limited.

Skin/eye effects: No reliable product-specific irritation or corrosion data are available. Mechanical or chemical irritation is possible.

Sensitization: No reliable product-specific respiratory or skin sensitization data are available. Peptide/protein-like materials may present an immunological sensitization concern for some individuals.

Mutagenicity, carcinogenicity, reproductive toxicity: No adequate product-specific occupational assessment is available. No ingredient is identified as an NTP, IARC, or OSHA-listed carcinogen in the matched formulation references reviewed for this release.

STOT / aspiration: No applicable product-specific information is available. Aspiration classification is generally not applicable to a dry solid but must be reassessed for any liquid formulation.

Immediate and delayed effects: Unknown systemic, pharmacological, allergic, or immunological effects may occur after unintended exposure. Severity may not correlate with the small packaged mass.

TOXICOLOGY DATA GAP

This section intentionally states where data are unavailable. OSHA Appendix D requires an SDS to say when no applicable information is available; missing data must not be converted into a claim of safety.

12. Ecological information

Ecotoxicity: No applicable product-specific information is available.

Persistence, degradability, bioaccumulation, and mobility: No applicable product-specific information is available. Avoid uncontrolled environmental release.

13. Disposal considerations

Waste disposal: Do not discharge to drains. Collect unused material, spill cleanup, contaminated PPE, and packaging in compatible closed containers. Characterize and dispose of waste through an authorized facility in accordance with federal, state, local, and facility requirements. Empty containers may retain residue.

14. Transport information

DOT / IATA / IMDG: Not regulated as dangerous goods based on the matched public formulation SDSs and the product as packaged. Shipment components such as dry ice, refrigerants, or batteries require their own transport assessment.

UN number / proper shipping name / class / packing group: Not applicable; no dangerous-goods UN number, proper shipping name, hazard class, or packing group is assigned to the product.

Special precautions: Protect vials from damage and temperature excursion. Dry ice, refrigerant, batteries, or other shipment components require their own transport assessment and documentation.

15. Regulatory information

OSHA Hazard Communication: Prepared and released in the 16-section format of 29 CFR 1910.1200 Appendix D. The product is not classified as hazardous under the adopted OSHA HCS determination.

Other regulatory status: Chemical-inventory, TSCA, state right-to-know, SARA, FDA, DEA, and international status have not been fully evaluated for the verified formulation. 'Research use only' is an intended-use restriction, not an exemption from applicable law.

16. Other information

Preparation date	2026-08-30
Revision	1.0 - initial released issue
Prepared for	ForgeOS Fulfillment LLC
Release status	RELEASED FOR DISTRIBUTION

Primary references

[OSHA 29 CFR 1910.1200 Appendix D - Safety Data Sheets \(Mandatory\)](#)

[MedChemExpress - BPC-157 acetate](#)

[PubChem - Thymosin beta-4](#)

[SourcePeptides - BPC-157 10 mg / TB-500 10 mg Wolverine SDS](#)

Formulation basis: ForgeOS responsible-party formulation representation dated 2026-08-30: Source Power products are the same chemical forms and formulations as the matched public reference SDSs.

Lot evidence reviewed: Lot 062226: BPC-157 5.32 mg; thymosin beta-4 5.15 mg; 99.02% peptide purity. Lot FH-BB20-01: BPC-157 10.65 mg; TB-500 10.23 mg; 20.88 mg total; 99.60% peptide purity.

Data quality and limitations: Prepared in good faith from the confirmed formulation, matched reference SDSs, and available lot COAs. Conservative controls apply where data are unavailable. Revise when material new information becomes available.